Replies to post #55057 on Biotech Values

[rkrw]

Thanks, that's helpful. So the market opportunity appears to be very small in Wilsons. IPF is a non starter. Insurance wont cover them without a successful, peer reviewed, controlled study. Plus they may price themselves out of it anyway.